Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept plus standard treatment in children with refractory lupus nephritis
ChiCTR2400081474Phase 2Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Mar 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telitacicept in lupus nephritis (LN) and systemic lupus erythematosus (SLE), sponsored by Children's Hospital of Fudan University. Primary endpoint: SRI-4 at Week 24. Started Mar 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2400081474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081474.